title: Alterations of primary fatty acid amides in serum of patients with severe mental illness.
abstract: Cannabis consumption is a well known risk factor for the onset of schizophrenia and evidence accumulates that the endocannabinoid system may play a central role in the disease etiology. Using a clinical bioinformatics approach, we have previously found primary fatty acid amides, which are linked to the endocannabinoid system, to be elevated in drug naive schizophrenia and affective disorder. Here, we provide a detailed description of these findings and expand the investigation by analyzing serum from 74 patients after short term treatment with antipsychotic medication using a liquid chromatography-mass spectrometry (LC-MS) metabolomics approach. We show that primary fatty acid amide (pFAA) levels normalize after treatment with typical but not after treatment with atypical antipsychotic medication. Also, the comparison of pFAA levels in schizophrenia patients to those of sleep deprived healthy volunteers suggests that pFAA abnormalities were not related to changes in the sleep architecture of patients with mental illness. Our findings support the involvement of the endocannabinoid system in the pathology of schizophrenia.
authors.affiliation: Institute of Biotechnology, University of Cambridge, Cambridge, UK.
authors.forename: Emanuel
authors.initials: E
authors.lastname: Schwarz
authors.forename: Phil
authors.initials: P
authors.lastname: Whitfield
authors.forename: Sven
authors.initials: S
authors.lastname: Nahnsen
authors.forename: Lan
authors.initials: L
authors.lastname: Wang
authors.forename: Hilary
authors.initials: H
authors.lastname: Major
authors.forename: F Markus
authors.initials: FM
authors.lastname: Leweke
authors.forename: Dagmar
authors.initials: D
authors.lastname: Koethe
authors.forename: Pietro
authors.initials: P
authors.lastname: Lio
authors.forename: Sabine
authors.initials: S
authors.lastname: Bahn
mesh_terms: D000577:Amides / Q000097:blood* / Q000378:metabolism; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D002186:Cannabinoids / Q000494:pharmacology; D002853:Chromatography, Liquid; D019295:Computational Biology; D005227:Fatty Acids / Q000378:metabolism*; D006801:Humans; D016018:Least-Squares Analysis; D013058:Mass Spectrometry; D055432:Metabolomics; D015233:Models, Statistical; D019964:Mood Disorders / Q000097:blood* / Q000188:drug therapy; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy; D012890:Sleep / Q000502:physiology
chemical_list: D000577:Amides; D014150:Antipsychotic Agents; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids; D005227:Fatty Acids